ASCO 2021 | Phase II MRD-adaptive trial of Elo-KRd for newly diagnosed myeloma

Benjamin Derman, MD, University of Chicago, Chicago, IL, discusses the findings of a Phase II measurable residual disease (MRD)-adaptive study investigating elotuzumab (Elo), carfilzomib (K), lenalidomide (R) and dexamethasone (Elo-KRd) for newly diagnosed patients with multiple myeloma. At the time of reporting, 44 patients were evaluable for response. MRD assessment by next generation sequencing (NGS) was undertaken after both 8 and 12 cycles of Elo-KRd. Patients who were MRD-negative after both cycle 9 and cycle 12 proceeded with Elo-Rd alone. Patients who were MRD-positive at cycle 12 received a further 12 cycles of Elo-KRd followed by Elo-Rd maintenance, and patients who converted to MRD-negativity between cycle 8 and cycle 12 received six additional cycles of Elo-KRd followed by Elo-Rd maintenance. Dr Derman gives an overview of the key findings of the disease and talks on its implications for clinical practice in the future. Dr Derman also comments on discordance between findings with NGS and mass spectrometry. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.